Alerts will be sent to your verified email
Verify Email
ZYDUSLIFE
|
Zydus Lifesciences
|
Mankind Pharma
|
Cipla
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
505.0 . | 67.0 . | 282.0 . |
|
Number of ANDA's Approved By USFDA
|
428.0 . | 48.0 . | 228.0 . |
|
Domestic Sales Growth - YoY
|
12.7 % | 8.4 % | 15.5 % |
|
US DMF Filings
|
147.0 . | n/a | 2472.0 . |
|
R&D as a % of Total Sales
|
8.8 % | 2.2 % | 7.0 % |
|
Financials
|
|||
|
5 yr Average ROE
|
18.47 % | 20.33 % | 13.9 % |
|
5yr average Equity Multiplier
|
1.52 | 1.46 | 1.25 |
|
5yr Average Asset Turnover Ratio
|
0.66 | 0.81 | 0.78 |
|
5yr Avg Net Profit Margin
|
19.02 % | 17.68 % | 14.31 % |
|
Price to Book
|
3.43 | 5.4 | 2.93 |
|
P/E
|
17.59 | 46.43 | 21.25 |
|
5yr Avg Cash Conversion Cycle
|
-84.89 Days | -13.08 Days | -4.31 Days |
|
Inventory Days
|
36.38 Days | 59.06 Days | 57.83 Days |
|
Days Receivable
|
36.93 Days | 34.35 Days | 50.64 Days |
|
Days Payable
|
160.15 Days | 121.69 Days | 105.99 Days |
|
5yr Average Interest Coverage Ratio
|
30.19 | 46.07 | 53.73 |
|
5yr Avg ROCE
|
19.65 % | 25.06 % | 19.36 % |
|
5yr Avg Operating Profit Margin
|
24.4 % | 24.62 % | 23.02 % |
|
5 yr average Debt to Equity
|
0.17 | 0.16 | 0.03 |
|
5yr CAGR Net Profit
|
16.23 % | 9.49 % | 17.0 % |
|
5yr Average Return on Assets
|
12.22 % | 14.46 % | 11.19 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
75.0 % | 72.66 % | 29.21 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.02 % | -3.84 % | -4.4 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-0.85 % | 7.47 % | 5.12 % |
|
Zydus Lifesciences
|
Mankind Pharma
|
Cipla
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Segment Break-Up
|
Segment Break-Up
|
-
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Operating Profit Break-Up
|
Operating Profit Break-Up
|
-
|
Operating Profit Break-Up
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|
|
Asset Break-Up
|
Asset Break-Up
|
-
|
Asset Break-Up
|